This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Innovative and adaptive strategies for new drug development are needed to maximize the potential of cell and gene therapies. CRA’s Lev Gerlovin with co-authors Walter Colasante and Pascale Diesel explain in this Cell and Gene article. Click here to read the article.
UPLs present opportunities for payers and financial challenges for pharmacies, leaving manufacturers with difficult choices. Lower per-script reimbursement to...
In this installment, we examine the relationship between launch prices in France and disease prevalence as reported in the Haute Autorité de Santé assessments.
CRA is a proud sponsor of the event, back for its 8th edition. This half-day, high-impact conference brings together top arbitrators, counsel, experts and...
CRA is a proud sponsor of Europe’s largest congress in market access, pricing and evidence featuring 250 speakers, 10 tracks and 1500+ attendees from pharma,...
